Provided by Tiger Trade Technology Pte. Ltd.

BioCardia

1.16
-0.0200-1.69%
Post-market: 1.160.00000.00%18:53 EDT
Volume:41.48K
Turnover:48.63K
Market Cap:12.69M
PE:-0.94
High:1.23
Open:1.20
Low:1.16
Close:1.18
52wk High:3.20
52wk Low:1.00
Shares:10.94M
Float Shares:4.05M
Volume Ratio:1.07
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2341
EPS(LYR):-1.2341
ROE:-950.12%
ROA:-144.98%
PB:14.18
PE(LYR):-0.94

Loading ...

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

GlobeNewswire
·
Dec 16, 2025

BioCardia Inc. Files Initial Beneficial Ownership Statement for Director Marvin Slosman

Reuters
·
Dec 11, 2025

BRIEF-Biocardia Announces Election Of New Board Director

Reuters
·
Dec 03, 2025

BioCardia Appoints Marvin Slosman to Board as Richard Krasno Departs

Reuters
·
Dec 03, 2025

Press Release: BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

Dow Jones
·
Dec 03, 2025

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

GlobeNewswire
·
Dec 01, 2025

BioCardia Appoints New VP of Quality

TIPRANKS
·
Nov 25, 2025

BioCardia Strengthens Leadership Team With the Addition of Farhan Shahab as Vice President of Quality

THOMSON REUTERS
·
Nov 24, 2025

Press Release: BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Dow Jones
·
Nov 24, 2025

BioCardia, Inc. Q3 Net Income USD -1.483 Million

Reuters
·
Nov 20, 2025

BioCardia’s Earnings Call: Progress Amid Financial Challenges

TIPRANKS
·
Nov 14, 2025

BioCardia’s Q3 2025: Clinical Progress and Financial Stability

TIPRANKS
·
Nov 13, 2025

Cellular therapy developer BioCardia's Q3 net loss narrows

Reuters
·
Nov 13, 2025

BRIEF-BioCardia, Inc. Q3 Net Income USD -1.483 Million

Reuters
·
Nov 13, 2025

BioCardia, Inc. Q3 Operating Income USD -1.488 Million

THOMSON REUTERS
·
Nov 13, 2025

BioCardia, Inc. Q3 Basic EPS USD -0.24

THOMSON REUTERS
·
Nov 13, 2025

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

GlobeNewswire
·
Nov 13, 2025

BioCardia reports Q3 net loss of $1.5 million on increased R&D expenses

Reuters
·
Nov 13, 2025

BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate

Benzinga
·
Nov 13, 2025

BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 Cardiamp HF Ii Cell Therapy Pivotal Trial

THOMSON REUTERS
·
Nov 10, 2025